Ruthigen Inc. (RTGN) 5.06 $RTGN
A Dozen Reasons To Love Dermatology Companies
ACCESSWIRE - Tue Jul 14, 8:25AM CDT
WHITEFISH, MT / ACCESSWIRE / July 14, 2015 / There are a number of reasons investors worldwide love dermatology companies. For starters, support of innovation has been key in gaining a far better understanding of skin conditions and advancing effective, safe therapies capable of becoming standards of care. Of course, Wall Street loves upside potential. At a more granular level, the logic underscoring dermatology as a good investment is quite diverse. As David M. Steinberg, Managing Director Equity Research at Jeffries, puts it, dermatology products have several general attributes: 1) shorter development timelines; 2) lower clinical trial costs; 3) perceived lower regulatory hurdles; 4) high cash pay components for aesthetics; 5) a recent track record of success; and 6) a really active M&A market, which Mr. Steinberg described as a second way for shareholders to win. Oculus Innovative Sciences' (NASDAQ: OCLS) CFO Bob Miller and CEO Jim Schutz expanded on Steinberg's view in the company's June earnings call, adding 7) derm has strong pricing, product margins, and insurance coverage;
it is a concentrated call point, meaning companies don't need an enormous sales force to cover; 9) derm has fast sales ramps; and 10) dermatology has great valuations or multiples on revenue.
VRX: 21.15 (-1.15), DERM: 33.33 (-0.23), ANAC: 99.06 (-0.14), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28), NVS: 83.20 (-0.06)
Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
GlobeNewswire - Tue Jun 16, 5:00AM CDT
-- Ruthigen/Pulmatrix merger closed on June 15, 2015, enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015
OCLSW: 0.30 (unch), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
These Biotech Stocks Could Deliver Big Returns for Investors
ACCESSWIRE - Mon Jun 15, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2015 / This week's events will be focused on the ongoing Greece negotiations with creditors, the largest among them being the IMF, the ECB and Germany. Additionally the FOMC minutes will be released this week pointing investors to clues as to whether the Fed is still patient regarding the proposed first rate hike. Our opinion at UltimateStockAlerts.com has been consistent on this topic for over 3 years now:
IDRA: 1.77 (+0.05), SNSS: 0.67 (+0.02), RTGN: 5.06 (+1.01), XOMA: 0.66 (-0.01)
Oculus Beats Consensus Sales Expectations by 30 Percent, Turnaround Plan Working
ACCESSWIRE - Mon Jun 15, 8:28AM CDT
WHITEFISH, MT / ACCESSWIRE / June 15, 2015 / At the end of May, shares of Oculus Innovative Sciences (NASDAQ: OCLS) broke above their 50 day moving average, a technical resistance at 90 cents and another at $1.05. The move continued to fill a previously open gap at $1.08 and take shares above their 200 day moving average, a sign of bullishness in technical analysis, as the stock printed as high as $1.97 on Tuesday. From the May low of 65 cents, the stock made a bottom-to-top move of 203%. All of this upward movement is important, as the company has received a delisting notice from NASDAQ for deficient bid price. The stock needs to close above $1 for 10 consecutive days in order to satisfy NASDAQ requirements for continued listing. Through June 12, the closing price was above $1 for eight consecutive days.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Ruthigen and Pulmatrix Stockholders Approve Merger
PR Newswire - Fri Jun 12, 3:01PM CDT
Ruthigen, Inc. ("Ruthigen"
(NASDAQ: RTGN) and Pulmatrix Inc. ("Pulmatrix" today announced that at Ruthigen's special meeting of stockholders held on June 12, 2015, Ruthigen obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Ruthigen and Pulmatrix. Pulmatrix previously obtained a sufficient number of written consents from its stockholders to consummate the merger.
RTGN: 5.06 (+1.01)
Panning for Golden Stocks Outside the Gold Industry
ACCESSWIRE - Thu May 28, 4:51PM CDT
WHITEFISH, MT / ACCESSWIRE / May 28, 2015 / Gold miners are their own special breed, utilizing skills most laymen do not understand to analyze the ground, drilling to confirm targets and digging-in to unearth the precious yellow metal. Throughout the world, though, there are still plenty of artisanal miners finding gold and others plucking a nugget from a pan that they stuck in a stream. Whatever the method, it often takes poring through plenty of material and some savvy vision to find the payoff, a tactic that can be applied to many applications in life, including the stock market.
ABT: 45.21 (+0.46), PHG: 26.50 (-0.06), PDCO: 49.52 (+0.16), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28), NBY: 2.37 (+0.03)
Antifungals, an Overlooked Biotech Niche With Big Potential
ACCESSWIRE - Wed May 20, 7:37AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true from before the late 19th century when the germ theory of disease became widely accepted. Before then, the hospital - a place that is designed to heal the sick - was just about the best place on Earth to contract a life-threatening infection due to unsanitary surgical procedures. This is still sadly true today as well. Hospitals are still the largest breeding grounds for deadly superbug infections due to the very sanitation procedures meant to stop them.
CDTX: 12.05 (+0.16), RTGN: 5.06 (+1.01)
IPOs & Transactions Week in Review: April 13 - 17 / plus video: M&A expert panel answer 12 questions
PR Newswire - Mon Apr 20, 10:50AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
SFBS: 50.50 (-0.13), RTGN: 5.06 (+1.01)
Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 5:33PM CDT
Ruthigen, Inc. (RTGN) and Pulmatrix entered into a definitive merger agreement upon the closing of which Pulmatrix will become a wholly-owned subsidiary of Ruthigen.
CYTK: 11.42 (+0.30), LCI: 31.85 (+0.63), SLXP: 172.96 (+0.15), RTGN: 5.06 (+1.01)
Ruthigen and Pulmatrix Enter into Merger Agreement
PR Newswire - Mon Mar 16, 6:00AM CDT
Ruthigen, Inc. (NASDAQ: RTGN), a biopharmaceutical company ("Ruthigen", and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company ("Pulmatrix", announced today that on March 13, 2015, they have entered into a definitive merger agreement. Upon the closing of the transactions contemplated by the merger agreement, Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen. In connection with Pulmatrix's entry into the merger agreement, certain existing institutional investors in Pulmatrix entered into stock purchase agreements with Pulmatrix to invest an additional $10,000,000 in Pulmatrix upon the closing of the merger. Pulmatrix also raised approximately $4,500,000 in February 2015, in contemplation of entering into the merger agreement.
RTGN: 5.06 (+1.01)
Oculus Innovative Sciences sells 350,000 Ruthigen stock at USD2.75 per share in USD962,500 non-dilutive funding
M2 - Mon Mar 16, 4:32AM CDT
Pharmaceutical company Oculus Innovative Sciences (NASDAQ:OCLS) reported on Friday the sale of 350,000 shares of Ruthigen (Nasdaq:RTGN) stock to an undisclosed investor group at USD2.75 per share for non-dilutive funding of USD962,500.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in Non-Dilutive Funding
GlobeNewswire - Mon Mar 16, 2:05AM CDT
-- Additional $4.5 million in non-dilutive funding in sale of remaining 1.65 million Ruthigen shares upon closing of Ruthigen/Pulmatrix merger expected by no later than August 2015
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
-- Total revenue of $3.2 million for the third quarter
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences to divest Ruthigen shares for USD5.5m in event of Ruthigen merger
M2 - Mon Jan 12, 6:53AM CST
Pharmaceutical company Oculus Innovative Sciences (NasdaqCM:OCLS) reported on Monday the launch of a securities purchase agreement with two current Ruthigen investors.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
A Dozen Reasons To Love Dermatology Companies
ACCESSWIRE - Tue Jul 14, 8:25AM CDT
WHITEFISH, MT / ACCESSWIRE / July 14, 2015 / There are a number of reasons investors worldwide love dermatology companies. For starters, support of innovation has been key in gaining a far better understanding of skin conditions and advancing effective, safe therapies capable of becoming standards of care. Of course, Wall Street loves upside potential. At a more granular level, the logic underscoring dermatology as a good investment is quite diverse. As David M. Steinberg, Managing Director Equity Research at Jeffries, puts it, dermatology products have several general attributes: 1) shorter development timelines; 2) lower clinical trial costs; 3) perceived lower regulatory hurdles; 4) high cash pay components for aesthetics; 5) a recent track record of success; and 6) a really active M&A market, which Mr. Steinberg described as a second way for shareholders to win. Oculus Innovative Sciences' (NASDAQ: OCLS) CFO Bob Miller and CEO Jim Schutz expanded on Steinberg's view in the company's June earnings call, adding 7) derm has strong pricing, product margins, and insurance coverage;
it is a concentrated call point, meaning companies don't need an enormous sales force to cover; 9) derm has fast sales ramps; and 10) dermatology has great valuations or multiples on revenue. VRX: 21.15 (-1.15), DERM: 33.33 (-0.23), ANAC: 99.06 (-0.14), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28), NVS: 83.20 (-0.06)
Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
GlobeNewswire - Tue Jun 16, 5:00AM CDT
-- Ruthigen/Pulmatrix merger closed on June 15, 2015, enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015
OCLSW: 0.30 (unch), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
These Biotech Stocks Could Deliver Big Returns for Investors
ACCESSWIRE - Mon Jun 15, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2015 / This week's events will be focused on the ongoing Greece negotiations with creditors, the largest among them being the IMF, the ECB and Germany. Additionally the FOMC minutes will be released this week pointing investors to clues as to whether the Fed is still patient regarding the proposed first rate hike. Our opinion at UltimateStockAlerts.com has been consistent on this topic for over 3 years now:
IDRA: 1.77 (+0.05), SNSS: 0.67 (+0.02), RTGN: 5.06 (+1.01), XOMA: 0.66 (-0.01)
Oculus Beats Consensus Sales Expectations by 30 Percent, Turnaround Plan Working
ACCESSWIRE - Mon Jun 15, 8:28AM CDT
WHITEFISH, MT / ACCESSWIRE / June 15, 2015 / At the end of May, shares of Oculus Innovative Sciences (NASDAQ: OCLS) broke above their 50 day moving average, a technical resistance at 90 cents and another at $1.05. The move continued to fill a previously open gap at $1.08 and take shares above their 200 day moving average, a sign of bullishness in technical analysis, as the stock printed as high as $1.97 on Tuesday. From the May low of 65 cents, the stock made a bottom-to-top move of 203%. All of this upward movement is important, as the company has received a delisting notice from NASDAQ for deficient bid price. The stock needs to close above $1 for 10 consecutive days in order to satisfy NASDAQ requirements for continued listing. Through June 12, the closing price was above $1 for eight consecutive days.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Ruthigen and Pulmatrix Stockholders Approve Merger
PR Newswire - Fri Jun 12, 3:01PM CDT
Ruthigen, Inc. ("Ruthigen"
(NASDAQ: RTGN) and Pulmatrix Inc. ("Pulmatrix" today announced that at Ruthigen's special meeting of stockholders held on June 12, 2015, Ruthigen obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Ruthigen and Pulmatrix. Pulmatrix previously obtained a sufficient number of written consents from its stockholders to consummate the merger. RTGN: 5.06 (+1.01)
Panning for Golden Stocks Outside the Gold Industry
ACCESSWIRE - Thu May 28, 4:51PM CDT
WHITEFISH, MT / ACCESSWIRE / May 28, 2015 / Gold miners are their own special breed, utilizing skills most laymen do not understand to analyze the ground, drilling to confirm targets and digging-in to unearth the precious yellow metal. Throughout the world, though, there are still plenty of artisanal miners finding gold and others plucking a nugget from a pan that they stuck in a stream. Whatever the method, it often takes poring through plenty of material and some savvy vision to find the payoff, a tactic that can be applied to many applications in life, including the stock market.
ABT: 45.21 (+0.46), PHG: 26.50 (-0.06), PDCO: 49.52 (+0.16), RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28), NBY: 2.37 (+0.03)
Antifungals, an Overlooked Biotech Niche With Big Potential
ACCESSWIRE - Wed May 20, 7:37AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true from before the late 19th century when the germ theory of disease became widely accepted. Before then, the hospital - a place that is designed to heal the sick - was just about the best place on Earth to contract a life-threatening infection due to unsanitary surgical procedures. This is still sadly true today as well. Hospitals are still the largest breeding grounds for deadly superbug infections due to the very sanitation procedures meant to stop them.
CDTX: 12.05 (+0.16), RTGN: 5.06 (+1.01)
IPOs & Transactions Week in Review: April 13 - 17 / plus video: M&A expert panel answer 12 questions
PR Newswire - Mon Apr 20, 10:50AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
SFBS: 50.50 (-0.13), RTGN: 5.06 (+1.01)
Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 5:33PM CDT
Ruthigen, Inc. (RTGN) and Pulmatrix entered into a definitive merger agreement upon the closing of which Pulmatrix will become a wholly-owned subsidiary of Ruthigen.
CYTK: 11.42 (+0.30), LCI: 31.85 (+0.63), SLXP: 172.96 (+0.15), RTGN: 5.06 (+1.01)
Ruthigen and Pulmatrix Enter into Merger Agreement
PR Newswire - Mon Mar 16, 6:00AM CDT
Ruthigen, Inc. (NASDAQ: RTGN), a biopharmaceutical company ("Ruthigen"
, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company ("Pulmatrix", announced today that on March 13, 2015, they have entered into a definitive merger agreement. Upon the closing of the transactions contemplated by the merger agreement, Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen. In connection with Pulmatrix's entry into the merger agreement, certain existing institutional investors in Pulmatrix entered into stock purchase agreements with Pulmatrix to invest an additional $10,000,000 in Pulmatrix upon the closing of the merger. Pulmatrix also raised approximately $4,500,000 in February 2015, in contemplation of entering into the merger agreement. RTGN: 5.06 (+1.01)
Oculus Innovative Sciences sells 350,000 Ruthigen stock at USD2.75 per share in USD962,500 non-dilutive funding
M2 - Mon Mar 16, 4:32AM CDT
Pharmaceutical company Oculus Innovative Sciences (NASDAQ:OCLS) reported on Friday the sale of 350,000 shares of Ruthigen (Nasdaq:RTGN) stock to an undisclosed investor group at USD2.75 per share for non-dilutive funding of USD962,500.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in Non-Dilutive Funding
GlobeNewswire - Mon Mar 16, 2:05AM CDT
-- Additional $4.5 million in non-dilutive funding in sale of remaining 1.65 million Ruthigen shares upon closing of Ruthigen/Pulmatrix merger expected by no later than August 2015
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
-- Total revenue of $3.2 million for the third quarter
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
Oculus Innovative Sciences to divest Ruthigen shares for USD5.5m in event of Ruthigen merger
M2 - Mon Jan 12, 6:53AM CST
Pharmaceutical company Oculus Innovative Sciences (NasdaqCM:OCLS) reported on Monday the launch of a securities purchase agreement with two current Ruthigen investors.
RTGN: 5.06 (+1.01), OCLS: 4.01 (-0.28)
